Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4246 to 4260 of 8905 results

  1. Single‑incision laparoscopic cholecystectomy (HTG361)

    Evidence-based recommendations on single incision laparoscopic cholecystectomy. This involves removing the gallbladder through a small cut, most often below the bellly button.

  2. Minimally invasive video‑assisted parathyroidectomy (HTG350)

    Evidence-based recommendations on minimally invasive video-assisted parathyroidectomy. This involves inserting surgical instruments through a small cut (keyhole surgery) to find and remove any abnormal glands.

  3. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  4. Photochemical corneal collagen cross‑linkage using riboflavin and ultraviolet A for keratoconus and keratectasia (HTG319)

    Evidence-based recommendations on photochemical corneal cross linkage using riboflavin and ultraviolet A for keratoconus. This involves using special eye drops and exposing the eye ultraviolet light, with the aim to strengthen the cornea.

  5. Selective internal radiation therapy for primary hepatocellular carcinoma (HTG314)

    Evidence-based recommendations on selective internal radiation therapy (SIRT) for primary hepatocellular carcinoma. This involves infusion of microspheres loaded with yttrium-90, which aims to deliver radiation directly into the tumour, minimising the risk of radiation damage to healthy surrounding tissues.

  6. Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)

    Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.

  7. Depth of anaesthesia monitors – Bispectral Index (BIS), E-Entropy and Narcotrend-Compact M (HTG292)

    Evidence-based recommendations on 3 electroencephalography (EEG)-based depth of anaesthesia monitors for assessing a patient’s response to anaesthetic drugs during surgery. The monitors are Bispectral Index (BIS), E-Entrophy and Narcotrend-Compact M.

  8. NICE: backing the healthtech that changes lives

    Following the government’s 10 Year Health Plan for England, we're strengthening our role in getting the best healthtech, including digital tools, diagnostics and medical devices, to patients.

  9. Topic prioritisation

    Find out what guidance is being considered for development

  10. Guidance, NICE advice and quality standards in development

    View a complete list of all our guidance, NICE advice and quality standards currently in development

  11. Guidance and quality standards awaiting development

    Find out which guidance and quality standards are awaiting development

  12. Therapeutic monitoring of TNF-alpha inhibitors in Crohn's disease (LISA-TRACKER ELISA kits, IDKmonitor ELISA kits, and Promonitor ELISA kits) (HTG401)

    Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease.

  13. Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (HTG360)

    Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the dose of 5-FU.

  14. Detecting, managing and monitoring haemostasis: viscoelastometric point‑of‑care testing (ROTEM, TEG and Sonoclot systems) (HTG348)

    Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems).

  15. EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (HTG316)

    Evidence-based recommendations on testing for epidermal growth factor receptor tyrosine kinase (EGFR–TK) mutations in untreated, locally advanced or metastatic non-small-cell-lung cancer.